Unique ID issued by UMIN | UMIN000047430 |
---|---|
Receipt number | R000054059 |
Scientific Title | Clinical study on the effect of metyrosine on improving physiological and metabolic disorders in patients with pheochromocytoma/paraganglioma. |
Date of disclosure of the study information | 2022/04/11 |
Last modified on | 2022/04/07 16:15:52 |
Clinical study on the effect of metyrosine on improving physiological and metabolic disorders in patients with pheochromocytoma/paraganglioma.
Clinical study on the effect of metyrosine on improving physiological and metabolic disorders in patients with pheochromocytoma/paraganglioma.
Clinical study on the effect of metyrosine on improving physiological and metabolic disorders in patients with pheochromocytoma/paraganglioma.
Clinical study on the effect of metyrosine on improving physiological and metabolic disorders in patients with pheochromocytoma/paraganglioma.
Japan |
pheochromocytoma/paraganglioma(PPGL)
Endocrinology and Metabolism |
Others
NO
To confirm efficacies of metyrosine administration in preoperative periods to the patients with PPGL.
Efficacy
Glucose metabolism(fasting blood glucose level,IRI,CPR,HOMA-beta,HOMA-IR)and decreased amount of catecholamines before and after administration of metyrosine.
Systolic and diastolic blood pressure and endocrine function (PRL, TSH, FT4, GH, IGF-1, PRA, PAC) before and after administration of metyrosine.
Blood pressure fluctuation, blood transfusion volume, urine volume, bleeding volume, phentolamine dose (mg), catecholamine usage before and after surgery.
Observational
20 | years-old | <= |
80 | years-old | > |
Male and Female
Select the one that meets all of the following criteria
・Patients aged between 20 and 80 years old
・Patients who have given written consent to participate in the study.
However, if you have dementia or mental illness, the patient who obtained the consent of the substitute
・Patients who can or have undergone blood and urinalysis before and after PPGL treatment
Those who meet any of the following criteria are excluded from the target
・Patients with severe renal dysfunction(eGFR <30 mL/min)
・Lactating patients
・Patients judged by the principal investigator and the research coordinator to be inappropriate as research subjects
15
1st name | Yuko |
Middle name | |
Last name | Matsuo |
Kurume University School of Medicine
Department of Internal Medicine, Division of Endocrinology and Metabolism
8300011
67 Asahi-machi, Kurume city Fukuoka, JAPAN
0942317563
matsuo_yuuko@med.kurume-u.ac.jp
1st name | Yuko |
Middle name | |
Last name | Matsuo |
Kurume University School of Medicine
Department of Internal Medicine, Division of Endocrinology and Metabolism
8300011
67 Asahi-machi, Kurume city Fukuoka, JAPAN
0942317563
matsuo_yuuko@med.kurume-u.ac.jp
Kurume University
none
Other
Ethics committee of Kurume University School of Medicine
67 Asahi-machi, Kurume city Fukuoka, JAPAN
0942653749
i_rinri@kurume-u.ac.jp
NO
2022 | Year | 04 | Month | 11 | Day |
Unpublished
12
Completed
2019 | Year | 04 | Month | 01 | Day |
2020 | Year | 10 | Month | 15 | Day |
2020 | Year | 10 | Month | 15 | Day |
2024 | Year | 03 | Month | 31 | Day |
The purpose of this study is to confirm the effectiveness of metyrosine administration for physiological, metabolic, and endocrinological functions in the preoperative period of PPGL patients compared to surgical treatment.
2022 | Year | 04 | Month | 07 | Day |
2022 | Year | 04 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000054059
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |